首页> 外文期刊>Journal of Experimental Pharmacology >A2A adenosine receptor-mediated increase in coronary flow in hyperlipidemic APOE–knockout mice
【24h】

A2A adenosine receptor-mediated increase in coronary flow in hyperlipidemic APOE–knockout mice

机译:A2A腺苷受体介导的高脂血症性APOE基因敲除小鼠冠状动脉血流增加

获取原文
       

摘要

Abstract: Adenosine-induced coronary vasodilation is predominantly A2A adenosine receptor (AR)-mediated, whereas A1 AR is known to negatively modulate the coronary flow (CF). However, the coronary responses to adenosine in hyperlipidemia and atherosclerosis are not well understood. Using hyperlipidemic/atherosclerotic apolipoprotein E (APOE)–knockout mice, CF responses to nonspecific adenosine agonist (5'-N-ethylcarboxamide adenosine, NECA) and specific adenosine agonists (2-chloro-N6-cyclopentyl-adenosine [CCPA, A1 AR-specific] and CGS-21680, A2A AR-specific) were assessed using isolated Langendorff hearts. Western blot analysis was performed in the aorta from APOE and their wild-type (WT) control (C57BL/6J). Baseline CF (expressed as mL/min/g heart weight) was not different among WT (13.23 ± 3.58), APOE (13.22 ± 2.78), and APOE on high-fat diet (HFD) for 12 weeks (APOE-HFD, 12.37 ± 4.76). Concentration response curves induced by CGS-21680 were significantly shifted to the left in APOE and APOE-HFD when compared with WT. CCPA induced an increase in CF only at 10-6 M in all groups and the effect was reversed by the addition of a selective A2A AR antagonist, SCH-58261 (10-6 M), and a significant decrease in CF from baseline was observed. Western blot analysis showed a significant upregulation of A2A AR in the aorta from APOE and APOE-HFD. This study provides the first evidence that CF responses to A2A AR stimulation were upregulated in hyperlipidemic/atherosclerotic animals. The speculation is that the use of A2A AR-specific agonist for myocardial perfusion imaging (such as regadenoson) could overestimate the coronary reserve in coronary artery disease patients.
机译:摘要:腺苷诱导的冠状血管舒张主要是由A2A腺苷受体(AR)介导的,而已知A1 AR会对冠脉流量(CF)产生负调节作用。然而,人们对高脂血症和动脉粥样硬化中冠状动脉对腺苷的反应尚不十分了解。使用高脂血症/动脉粥样硬化载脂蛋白E(APOE)敲除小鼠,CF对非特异性腺苷激动剂(5'-N-乙基羧酰胺腺苷,NECA)和特定腺苷激动剂(2-氯-N6-环戊基腺苷[CCPA,A1 AR-特异性]和CGS-21680(A2A AR特异性)进行评估,使用孤立的Langendorff心脏。在来自APOE及其野生型(WT)对照(C57BL / 6J)的主动脉中进行蛋白质印迹分析。 WT(13.23±3.58),APOE(13.22±2.78)和高脂饮食(HFD)持续12周的APOE(APOE-HFD,12.37)之间的基线CF(以mL / min / g心重表示)无差异±4.76)。与WT相比,CGS-21680诱导的浓度响应曲线在APOE和APOE-HFD中显着向左移动。 CCPA在所有组中仅在10-6 M时诱导CF升高,并且通过添加选择性A2A AR拮抗剂SCH-58261(10-6 M)来逆转该作用,并且观察到CF从基线显着降低。蛋白质印迹分析显示,主动脉中的APOE和APOE-HFD显着上调了A2A AR。这项研究提供了第一个证据,表明高脂血症/动脉粥样硬化动物的CF对A2A AR刺激的反应被上调。推测使用A2A AR特异性激动剂进行心肌灌注显像(例如regadenoson)可能会高估冠状动脉疾病患者的冠脉储备。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号